Respiratory Medicine clinical trials
Alfred Respiratory Medicine has a long and internationally recognised track record in clinical trials. Across a wide range of respiratory conditions, including rare and advanced diseases, we have helped establish novel drug therapies, devices and behavioural treatments. We are a leader in early and late phase clinical trials and implementation studies. We led and completed many investigator-initiated studies, as well as being leading co-investigators in large international multi-centre studies.
Why are clinical trials so important?
We need clinical trials to prove that a new medication, device or treatment is safe and effective for people.
Without clinical trials, new treatments and medicines cannot be approved for use in Australia.
Find out more about clinical trialsAbout us
Our program trials new respiratory treatments across the entire research pipeline, and is the only Australian program that can provide a comprehensive bench-to-bed drug discovery pathway on one site including:
- Target discovery
- Pre-clinical drug and biomarker evaluation
- Phase I clinical trials, including first-in-human and first-in-disease studies
- Phase II clinical trials
- Large scale multicentre Phase III and IV trials
Our clinical trials capacity is enhanced by:
- Precise clinically phenotyping of enrolled patients
- Prospective clinical registries linked to a range of tissue and blood biobanks, supported by laboratories expert in pre-clinical research
- Internationally recognised and highly experienced clinician trialists, expert in a broad range of advanced and rare lung diseases
- Well characterised and large patient cohorts
- State-of-the-art diagnostic services, including imaging, bronchoscopy, and respiratory and sleep physiology services
Find out more about our Respiratory Medicine research.
What are Phase I, II, III or IV clinical trials?
There are four different phases of a clinical trial. Each phase is represented by a roman numeral.
Find out more about what happens in each phase
Our vision
- Bring new therapies to patients with respiratory disease, allergy and sleep disorders that address the current care gaps. We do this by partnering with patients, health professionals, researchers and industry, to develop innovative treatments and enhance access to transformational clinical care.
Our focus
We conduct clinical trials of new treatments for respiratory disorders including:
- Interstitial lung disease
- Pulmonary hypertension
- Asthma and allergy
- Cystic fibrosis
- COPD
- Lung transplantation
- Lung cancer
- Occupational lung disease
Our achievements
- Lead site for trials of a novel T-cell epitope-based peptide therapy for peanut allergy
- First-in-disease studies of bronchoscopic lung volume reduction
- Key Australian site for multiple late phase trials of anti-fibrotic treatment in pulmonary fibrosis
- Lead site for next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector
- Lead site for a late phase device trial to treat exertional hypoxemia in advanced lung disease
Our team
The Respiratory Medicine department, led by Prof Trevor Williams has extensive leadership experience in leading clinical trials.
Our clinical trial leads are:
- Prof Mark Hew and Prof Robyn O’Hehir - asthma and allergy
- Prof Greg Snell and Prof Glen Westall - lung transplantation
- A/Prof Dominic Keating - cystic fibrosis
- A/Prof Rob Stirling - bronchiectasis
- Prof Trevor Williams - pulmonary hypertension and COPD
- A/Prof Ian Glaspole and Prof Glen Westall - lung fibrosis
- Prof Matthew Naughton - sleep disorders
- Prof Anne Holland and A/Prof Natasha Smallwood - devices and behavioural interventions
Are you interested in our clinical trials?
ClinTrial Refer is a quick way to see all of our open trials, in one place. It’s the easy way to find a trial that may be right for you or your patient.
Find Respiratory Medicine clinical trials on ClinTrial Refer
